Patents by Inventor Douglas Stuart Greene
Douglas Stuart Greene has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115708Abstract: The presently disclosed subject matter provides a formulation for the use of 1-deoxygalactonojirimycin and/or enzyme replacement therapy for the treatment of Fabry disease.Type: ApplicationFiled: July 17, 2023Publication date: April 11, 2024Applicant: Amicus Therapeutics, Inc.Inventors: Douglas Stuart Greene, Kenneth Valenzano
-
Publication number: 20230256190Abstract: Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.Type: ApplicationFiled: April 19, 2023Publication date: August 17, 2023Applicant: Mallinckrodt Hospital Products IP Unlimited CompanyInventors: Brahm Goldstein, Douglas Stuart Greene
-
Patent number: 11660416Abstract: Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.Type: GrantFiled: February 10, 2020Date of Patent: May 30, 2023Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Brahm Goldstein, Douglas Stuart Greene
-
Publication number: 20230003747Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.Type: ApplicationFiled: September 12, 2022Publication date: January 5, 2023Inventors: Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
-
Patent number: 11474115Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.Type: GrantFiled: February 27, 2020Date of Patent: October 18, 2022Assignee: Mallinckrodt Pharmaceuticals Ireland LimitedInventors: Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
-
Publication number: 20200268890Abstract: The presently disclosed subject matter provides a formulation for the use of 1-deoxygalactonojirimycin and/or enzyme replacement therapy for the treatment of Fabry disease.Type: ApplicationFiled: March 2, 2020Publication date: August 27, 2020Applicant: Amicus Therapeutics, Inc.Inventors: Douglas Stuart Greene, Kenneth Valenzano
-
Publication number: 20200200773Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.Type: ApplicationFiled: February 27, 2020Publication date: June 25, 2020Inventors: Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
-
Publication number: 20200171264Abstract: Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.Type: ApplicationFiled: February 10, 2020Publication date: June 4, 2020Applicant: Mallinckrodt Hospital Products IP LimitedInventors: Brahm Goldstein, Douglas Stuart Greene
-
Patent number: 10613103Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.Type: GrantFiled: June 18, 2015Date of Patent: April 7, 2020Assignee: Mallinckrodt Hospital Products IP LimitedInventors: Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
-
Patent number: 10556086Abstract: Methods of administering therapeutic gases containing high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also, methods of administering a therapeutic gas containing nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods can also include intermittent administration of nitric oxide pulses.Type: GrantFiled: March 14, 2013Date of Patent: February 11, 2020Assignee: Mallinckrodt Hospital IP LimitedInventors: Brahm Goldstein, Douglas Stuart Greene
-
Publication number: 20180153999Abstract: The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease.Type: ApplicationFiled: October 12, 2017Publication date: June 7, 2018Inventors: Douglas Stuart Greene, Kenneth Valenzano
-
Publication number: 20170212133Abstract: Methods for identifying premature infants at risk for developing bronchopulmonary dysplasia and/or most likely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia (BPD). Methods for treating premature infants identified as at risk and/or likely to benefit are provided. also provided are methods for identifying premature infants that are not at risk for developing bronchopulmonary dysplasia and/or unlikely to benefit from administration of inhaled nitric oxide for prevention of bronchopulmonary dysplasia, and methods for avoiding risks of toxicity and undesirable side effects associated with inhaled nitric oxide therapy comprising administering only non-iNO treatment modalities to these infants.Type: ApplicationFiled: June 18, 2015Publication date: July 27, 2017Inventors: Douglas Stuart Greene, Joseph J. Medicis, Jim Potenziano
-
Publication number: 20150086530Abstract: The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin and enzyme replacement therapy for the treatment of Pompe disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin hydrochloride and alglucosidase alfa for the treatment of Pompe disease.Type: ApplicationFiled: May 2, 2013Publication date: March 26, 2015Inventors: Douglas Stuart Greene, Kenneth Joseph Valenzano
-
Publication number: 20140219986Abstract: The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease.Type: ApplicationFiled: March 8, 2012Publication date: August 7, 2014Applicant: AMICUS THERAPEUTICS ,INC.Inventors: Douglas Stuart Greene, Kenneth Joseph Valenzano
-
Publication number: 20130239963Abstract: Described are methods of administering therapeutic gases comprising high concentrations of nitric oxide, particularly concentrations above 2,000 ppm. The therapeutic gas may be administered at a certain dosing rate, such as less than 166 micrograms of nitric oxide per second. Also described are methods of administering a therapeutic gas comprising nitric oxide to a patient, wherein a dose of nitric oxide is administered from a portable device that includes a delivery system and a mini-cylinder. Methods of intermittent administration of nitric oxide pulses are also described.Type: ApplicationFiled: March 14, 2013Publication date: September 19, 2013Applicant: INO Therapeutics LLCInventors: Brahm Goldstein, Douglas Stuart Greene